Converting naloxone to OTC expected to increase sales

Converting naloxone to OTC expected to increase sales

(HealthDay)—The demand for naloxone is relatively inelastic with respect to changes in its out-of-pocket price, and conversion to an over-the-counter medication is expected to increase naloxone pharmacy sales, according to a study published online Feb. 20 in Health Services Research.

Sean M. Murphy, Ph.D., from the Weill Cornell Medical College in New York City, and colleagues used data from a nationwide prescription claims dataset for 2010 to 2017. The dataset covers 80 percent of U.S. retail pharmacies and about 90 percent of prescriptions filled. A longitudinal, simultaneous equation model of supply and demand was estimated.

The researchers found that a 1 percent increase in out-of-pocket price paid for naloxone would result in a decrease of 0.27 percent in sales on average. Following conversion to over-the-counter status, the authors predict that the total quantity of naloxone sold in pharmacies will increase between 15 and 179 percent.

"Converting naloxone from prescription-only to status is likely to lead to a substantial increase in total pharmacy sales," the authors write. "All else constant, as the prevalence of naloxone increases among the general public, so too should the opportunities to reverse , thereby giving overdose survivors another chance to initiate treatment."

One author disclosed financial ties to Sandoz.


Explore further

Let's talk about Rx use: Recognizing and reversing an overdose

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Health Services Research

Copyright © 2019 HealthDay. All rights reserved.

Citation: Converting naloxone to OTC expected to increase sales (2019, February 27) retrieved 19 August 2019 from https://medicalxpress.com/news/2019-02-naloxone-otc-sales.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more